Therapeutic Approaches for Dysferlinopathy in Animal Models

  • William Lostal
  • Isabelle RichardEmail author


Dysferlin deficiencies are responsible for muscular dystrophies with different presentations with the most frequent being limb-girdle muscular dystrophy type 2B and Miyoshi myopathy. The dysferlin (DYSF) gene is expressed through a 6.2 kb coding sequence, a size that impedes classical gene transfer approach using adeno-associated vectors (AAVs). There is no treatment for dysferlin deficiencies, but in the last decade, a large spectrum of strategies has been evaluated in different setups. In this review, we present the different models that are available for preclinical studies as well as the different therapeutic approaches evaluated so far. Among the latter, the most extensively studied strategies are AAV-mediated transfer of either full-length or truncated dysferlin using two or one AAV, RNA-based strategies such as exon skipping and trans-splicing, and overexpression of a protein proposed to compensate the absence of dysferlin. Gene editing and cell therapy have also been set off.


Dysferlin In vivo Treatment Mouse Skeletal muscle 


  1. 1.
    Bashir R, Britton S, Strachan T, Keers S, Vafiadaki E, Lako M, Richard I, Marchand S, Bourg N, Argov Z, Sadeh M, Mahjneh I, Marconi G, Passos-Bueno MR, Moreira Ede S, Zatz M, Beckmann JS, Bushby K (1998) A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B. Nat Genet 20(1):37–42PubMedGoogle Scholar
  2. 2.
    Bashir R, Strachan T, Keers S, Stephenson A, Mahjneh I, Marconi G, Nashef L, Bushby KM (1994) A gene for autosomal recessive limb-girdle muscular dystrophy maps to chromosome 2p. Hum Mol Genet 3(3):455–457PubMedGoogle Scholar
  3. 3.
    Liu J, Aoki M, Illa I, Wu C, Fardeau M, Angelini C, Serrano C, Urtizberea JA, Hentati F, Hamida MB, Bohlega S, Culper EJ, Amato AA, Bossie K, Oeltjen J, Bejaoui K, McKenna-Yasek D, Hosler BA, Schurr E, Arahata K, de Jong PJ, Brown RH Jr (1998) Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet 20(1):31–36PubMedGoogle Scholar
  4. 4.
    Nguyen K, Bassez G, Bernard R, Krahn M, Labelle V, Figarella-Branger D, Pouget J, Hammouda el H, Beroud C, Urtizberea A, Eymard B, Leturcq F, Levy N (2005) Dysferlin mutations in LGMD2B, Miyoshi myopathy, and atypical dysferlinopathies. Hum Mutat 26(2):165PubMedGoogle Scholar
  5. 5.
    Illa I, Serrano-Munuera C, Gallardo E, Lasa A, Rojas-Garcia R, Palmer J, Gallano P, Baiget M, Matsuda C, Brown RH (2001) Distal anterior compartment myopathy: a dysferlin mutation causing a new muscular dystrophy phenotype. Ann Neurol 49(1):130–134PubMedGoogle Scholar
  6. 6.
    Klinge L, Aboumousa A, Eagle M, Hudson J, Sarkozy A, Vita G, Charlton R, Roberts M, Straub V, Barresi R, Lochmuller H, Bushby K (2010) New aspects on patients affected by dysferlin deficient muscular dystrophy. J Neurol Neurosurg Psychiatry 81(9):946–953PubMedGoogle Scholar
  7. 7.
    Nguyen K, Bassez G, Krahn M, Bernard R, Laforet P, Labelle V, Urtizberea JA, Figarella-Branger D, Romero N, Attarian S, Leturcq F, Pouget J, Levy N, Eymard B (2007) Phenotypic study in 40 patients with dysferlin gene mutations: high frequency of atypical phenotypes. Arch Neurol 64(8):1176–1182PubMedGoogle Scholar
  8. 8.
    Pegoraro E, Hoffman EP (1993) Limb-Girdle Muscular Dystrophy Overview. doi:NBK1408 [bookaccession]Google Scholar
  9. 9.
    Selcen D, Stilling G, Engel AG (2001) The earliest pathologic alterations in dysferlinopathy. Neurology 56(11):1472–1481PubMedGoogle Scholar
  10. 10.
    Therrien C, Di Fulvio S, Pickles S, Sinnreich M (2009) Characterization of lipid binding specificities of dysferlin C2 domains reveals novel interactions with phosphoinositides. Biochemistry 48(11):2377–2384PubMedGoogle Scholar
  11. 11.
    Bansal D, Miyake K, Vogel SS, Groh S, Chen CC, Williamson R, McNeil PL, Campbell KP (2003) Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature 423(6936):168–172PubMedGoogle Scholar
  12. 12.
    Lek A, Evesson FJ, Lemckert FA, Redpath GM, Lueders AK, Turnbull L, Whitchurch CB, North KN, Cooper ST (2013) Calpains, cleaved mini-dysferlinC72, and L-type channels underpin calcium-dependent muscle membrane repair. J Neurosci 33(12):5085–5094PubMedGoogle Scholar
  13. 13.
    Anderson LV, Davison K, Moss JA, Young C, Cullen MJ, Walsh J, Johnson MA, Bashir R, Britton S, Keers S, Argov Z, Mahjneh I, Fougerousse F, Beckmann JS, Bushby KM (1999) Dysferlin is a plasma membrane protein and is expressed early in human development. Hum Mol Genet 8(5):855–861PubMedGoogle Scholar
  14. 14.
    Millay DP, Maillet M, Roche JA, Sargent MA, McNally EM, Bloch RJ, Molkentin JD (2009) Genetic manipulation of dysferlin expression in skeletal muscle: novel insights into muscular dystrophy. Am J Pathol 175(5):1817–1823PubMedPubMedCentralGoogle Scholar
  15. 15.
    Roche JA, Tulapurkar ME, Mueller AL, van Rooijen N, Hasday JD, Lovering RM, Bloch RJ (2015) Myofiber damage precedes macrophage infiltration after in vivo injury in dysferlin-deficient A/J mouse skeletal muscle. Am J Pathol 185(6):1686–1698PubMedPubMedCentralGoogle Scholar
  16. 16.
    Kobayashi K, Izawa T, Kuwamura M, Yamate J (2012) Dysferlin and animal models for dysferlinopathy. J Toxicol Pathol 25(2):135–147PubMedPubMedCentralGoogle Scholar
  17. 17.
    Weller AH, Magliato SA, Bell KP, Rosenberg NL (1997) Spontaneous myopathy in the SJL/J mouse: pathology and strength loss. Muscle Nerve 20(1):72–82PubMedGoogle Scholar
  18. 18.
    Bittner RE, Anderson LV, Burkhardt E, Bashir R, Vafiadaki E, Ivanova S, Raffelsberger T, Maerk I, Hoger H, Jung M, Karbasiyan M, Storch M, Lassmann H, Moss JA, Davison K, Harrison R, Bushby KM, Reis A (1999) Dysferlin deletion in SJL mice (SJL-Dysf) defines a natural model for limb girdle muscular dystrophy 2B. Nat Genet 23(2):141–142PubMedGoogle Scholar
  19. 19.
    Ho M, Post CM, Donahue LR, Lidov HG, Bronson RT, Goolsby H, Watkins SC, Cox GA, Brown RH Jr (2004) Disruption of muscle membrane and phenotype divergence in two novel mouse models of dysferlin deficiency. Hum Mol Genet 13(18):1999–2010PubMedGoogle Scholar
  20. 20.
    Han R, Frett EM, Levy JR, Rader EP, Lueck JD, Bansal D, Moore SA, Ng R, Beltran-Valero de Bernabe D, Faulkner JA, Campbell KP (2010) Genetic ablation of complement C3 attenuates muscle pathology in dysferlin-deficient mice. J Clin Invest 120(12):4366–4374PubMedPubMedCentralGoogle Scholar
  21. 21.
    Wenzel K, Zabojszcza J, Carl M, Taubert S, Lass A, Harris CL, Ho M, Schulz H, Hummel O, Hubner N, Osterziel KJ, Spuler S (2005) Increased susceptibility to complement attack due to down-regulation of decay-accelerating factor/CD55 in dysferlin-deficient muscular dystrophy. J Immunol 175(9):6219–6225PubMedGoogle Scholar
  22. 22.
    Lostal W, Bartoli M, Bourg N, Roudaut C, Bentaib A, Miyake K, Guerchet N, Fougerousse F, McNeil P, Richard I (2010) Efficient recovery of dysferlin deficiency by dual adeno-associated vector-mediated gene transfer. Hum Mol Genet 19(10):1897–1907PubMedGoogle Scholar
  23. 23.
    Baek JH, Many GM, Evesson FJ, Kelley VR (2017) Dysferlinopathy promotes an intramuscle expansion of macrophages with a cyto-destructive phenotype. Am J Pathol 187(6):1245–1257PubMedGoogle Scholar
  24. 24.
    Llanga T, Nagy N, Conatser L, Dial C, Sutton RB, Hirsch ML (2017) Structure-based designed nano-dysferlin significantly improves dysferlinopathy in BLA/J mice. Mol Ther 25(9):2150–2162PubMedPubMedCentralGoogle Scholar
  25. 25.
    Nagy N, Nonneman RJ, Llanga T, Dial CF, Riddick NV, Hampton T, Moy SS, Lehtimaki KK, Ahtoniemi T, Puolivali J, Windish H, Albrecht D, Richard I, Hirsch ML (2017) Hip region muscular dystrophy and emergence of motor deficits in dysferlin-deficient Bla/J mice. Physiol Rep 5(6):e13173PubMedPubMedCentralGoogle Scholar
  26. 26.
    Farini A, Sitzia C, Navarro C, D’Antona G, Belicchi M, Parolini D, Del Fraro G, Razini P, Bottinelli R, Meregalli M, Torrente Y (2012) Absence of T and B lymphocytes modulates dystrophic features in dysferlin deficient animal model. Exp Cell Res 318(10):1160–1174PubMedGoogle Scholar
  27. 27.
    Ma J, Pichavant C, du Bois H, Bhakta M, Calos MP (2017) DNA-mediated gene therapy in a mouse model of limb girdle muscular dystrophy 2B. Mol Ther Methods Clin Dev 7:123–131PubMedPubMedCentralGoogle Scholar
  28. 28.
    Wiktorowicz T, Kinter J, Kobuke K, Campbell KP, Sinnreich M (2015) Genetic characterization and improved genotyping of the dysferlin-deficient mouse strain Dysf (tm1Kcam). Skelet Muscle 5:323Google Scholar
  29. 29.
    Kawahara G, Serafini PR, Myers JA, Alexander MS, Kunkel LM (2011) Characterization of zebrafish dysferlin by morpholino knockdown. Biochem Biophys Res Commun 413(2):358–363PubMedPubMedCentralGoogle Scholar
  30. 30.
    Berger J, Currie PD (2012) Zebrafish models flex their muscles to shed light on muscular dystrophies. Dis Model Mech 5(6):726–732PubMedPubMedCentralGoogle Scholar
  31. 31.
    Duan D, Sharma P, Yang J, Yue Y, Dudus L, Zhang Y, Fisher KJ, Engelhardt JF (1998) Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J Virol 72(11):8568–8577PubMedPubMedCentralGoogle Scholar
  32. 32.
    Ghosh A, Yue Y, Duan D (2011) Efficient transgene reconstitution with hybrid dual AAV vectors carrying the minimized bridging sequences. Hum Gene Ther 22(1):77–83PubMedGoogle Scholar
  33. 33.
    Dunckley MG, Love DR, Davies KE, Walsh FS, Morris GE, Dickson G (1992) Retroviral-mediated transfer of a dystrophin minigene into mdx mouse myoblasts in vitro. FEBS Lett 296(2):128–134PubMedGoogle Scholar
  34. 34.
    Phelps SF, Hauser MA, Cole NM, Rafael JA, Hinkle RT, Faulkner JA, Chamberlain JS (1995) Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. Hum Mol Genet 4(8):1251–1258PubMedGoogle Scholar
  35. 35.
    Grose WE, Clark KR, Griffin D, Malik V, Shontz KM, Montgomery CL, Lewis S, Brown RH Jr, Janssen PM, Mendell JR, Rodino-Klapac LR (2012) Homologous recombination mediates functional recovery of Dysferlin deficiency following AAV5 gene transfer. PLoS One 7(6):e39233PubMedPubMedCentralGoogle Scholar
  36. 36.
    Pryadkina M, Lostal W, Bourg N, Charton K, Roudaut C, Hirsch ML, Richard I (2015) A comparison of AAV strategies distinguishes overlapping vectors for efficient systemic delivery of the 6.2 kb Dysferlin coding sequence. Mol Ther Methods Clin Dev 2:15009PubMedPubMedCentralGoogle Scholar
  37. 37.
    Potter RA, Griffin DA, Sondergaard PC, Johnson RW, Pozsgai ER, Heller KN, Peterson EL, Lehtimaki KK, Windish HP, Mittal PJ, Albrecht DE, Mendell JR, Rodino-Klapac LR (2017) Systemic delivery of Dysferlin overlap vectors provides long-term gene expression and functional improvement for dysferlinopathy. Hum Gene Ther 29(7):749–762PubMedGoogle Scholar
  38. 38.
    Sondergaard PC, Griffin DA, Pozsgai ER, Johnson RW, Grose WE, Heller KN, Shontz KM, Montgomery CL, Liu J, Clark KR, Sahenk Z, Mendell JR, Rodino-Klapac LR (2015) AAV.Dysferlin overlap vectors restore function in Dysferlinopathy animal models. Ann Clin Transl Neurol 2(3):256–270PubMedPubMedCentralGoogle Scholar
  39. 39.
    Krahn M, Wein N, Bartoli M, Lostal W, Courrier S, Bourg-Alibert N, Nguyen K, Vial C, Streichenberger N, Labelle V, DePetris D, Pecheux C, Leturcq F, Cau P, Richard I, Levy N (2010) A naturally occurring human minidysferlin protein repairs sarcolemmal lesions in a mouse model of dysferlinopathy. Sci Transl Med 2(50):50ra69PubMedGoogle Scholar
  40. 40.
    Lostal W, Bartoli M, Roudaut C, Bourg N, Krahn M, Pryadkina M, Borel P, Suel L, Roche JA, Stockholm D, Bloch RJ, Levy N, Bashir R, Richard I (2012) Lack of correlation between outcomes of membrane repair assay and correction of dystrophic changes in experimental therapeutic strategy in dysferlinopathy. PLoS One 7(5):e38036PubMedPubMedCentralGoogle Scholar
  41. 41.
    Aartsma-Rus A, Singh KH, Fokkema IF, Ginjaar IB, van Ommen GJ, den Dunnen JT, van der Maarel SM (2010) Therapeutic exon skipping for dysferlinopathies? Eur J Hum Genet 18(8):889–894PubMedPubMedCentralGoogle Scholar
  42. 42.
    Sinnreich M, Therrien C, Karpati G (2006) Lariat branch point mutation in the dysferlin gene with mild limb-girdle muscular dystrophy. Neurology 66(7):1114–1116PubMedGoogle Scholar
  43. 43.
    Wein N, Avril A, Bartoli M, Beley C, Chaouch S, Laforet P, Behin A, Butler-Browne G, Mouly V, Krahn M, Garcia L, Levy N (2010) Efficient bypass of mutations in dysferlin deficient patient cells by antisense-induced exon skipping. Hum Mutat 31(2):136–142PubMedGoogle Scholar
  44. 44.
    Barthelemy F, Blouin C, Wein N, Mouly V, Courrier S, Dionnet E, Kergourlay V, Mathieu Y, Garcia L, Butler-Browne G, Lamaze C, Levy N, Krahn M, Bartoli M (2015) Exon 32 skipping of Dysferlin rescues membrane repair in patients’ cells. J Neuromuscul Dis 2(3):281–290PubMedPubMedCentralGoogle Scholar
  45. 45.
    Dominov JA, Uyan O, Sapp PC, McKenna-Yasek D, Nallamilli BR, Hegde M, Brown RH Jr (2014) A novel dysferlin mutant pseudoexon bypassed with antisense oligonucleotides. Ann Clin Transl Neurol 1(9):703–720PubMedPubMedCentralGoogle Scholar
  46. 46.
    Meregalli M, Navarro C, Sitzia C, Farini A, Montani E, Wein N, Razini P, Beley C, Cassinelli L, Parolini D, Belicchi M, Parazzoli D, Garcia L, Torrente Y (2013) Full-length dysferlin expression driven by engineered human dystrophic blood derived CD133+ stem cells. FEBS J 280(23):6045–6060PubMedGoogle Scholar
  47. 47.
    Monjaret F, Bourg N, Suel L, Roudaut C, Le Roy F, Richard I, Charton K (2014) Cis-splicing and translation of the pre-trans-splicing molecule combine with efficiency in spliceosome-mediated RNA trans-splicing. Mol Ther 22(6):1176–1187PubMedPubMedCentralGoogle Scholar
  48. 48.
    Philippi S, Lorain S, Beley C, Peccate C, Precigout G, Spuler S, Garcia L (2015) Dysferlin rescue by spliceosome-mediated pre-mRNA trans-splicing targeting introns harbouring weakly defined 3′ splice sites. Hum Mol Genet 24(14):4049–4060PubMedGoogle Scholar
  49. 49.
    Cardenas AM, Gonzalez-Jamett AM, Cea LA, Bevilacqua JA, Caviedes P (2016) Dysferlin function in skeletal muscle: possible pathological mechanisms and therapeutical targets in dysferlinopathies. Exp Neurol 283(Pt A):246–254PubMedGoogle Scholar
  50. 50.
    Davis DB, Delmonte AJ, Ly CT, McNally EM (2000) Myoferlin, a candidate gene and potential modifier of muscular dystrophy. Hum Mol Genet 9(2):217–226PubMedGoogle Scholar
  51. 51.
    Doherty KR, Cave A, Davis DB, Delmonte AJ, Posey A, Earley JU, Hadhazy M, McNally EM (2005) Normal myoblast fusion requires myoferlin. Development 132(24):5565–5575PubMedPubMedCentralGoogle Scholar
  52. 52.
    Johnson CP, Chapman ER (2010) Otoferlin is a calcium sensor that directly regulates SNARE-mediated membrane fusion. J Cell Biol 191(1):187–197PubMedPubMedCentralGoogle Scholar
  53. 53.
    Bolduc V, Marlow G, Boycott KM, Saleki K, Inoue H, Kroon J, Itakura M, Robitaille Y, Parent L, Baas F, Mizuta K, Kamata N, Richard I, Linssen WH, Mahjneh I, de Visser M, Bashir R, Brais B (2010) Recessive mutations in the putative calcium-activated chloride channel Anoctamin 5 cause proximal LGMD2L and distal MMD3 muscular dystrophies. Am J Hum Genet 86(2):213–221PubMedPubMedCentralGoogle Scholar
  54. 54.
    Monjaret F, Suel-Petat L, Bourg-Alibert N, Vihola A, Marchand S, Roudaut C, Gicquel E, Udd B, Richard I, Charton K (2013) The phenotype of Dysferlin-deficient mice is not rescued by Adeno-associated virus-mediated transfer of Anoctamin 5. Hum Gene Ther Clin Dev 24:65–76PubMedGoogle Scholar
  55. 55.
    Cai C, Weisleder N, Ko JK, Komazaki S, Sunada Y, Nishi M, Takeshima H, Ma J (2009) Membrane repair defects in muscular dystrophy are linked to altered interaction between MG53, caveolin-3, and dysferlin. J Biol Chem 284(23):15894–15902PubMedPubMedCentralGoogle Scholar
  56. 56.
    He B, Tang RH, Weisleder N, Xiao B, Yuan Z, Cai C, Zhu H, Lin P, Qiao C, Li J, Mayer C, Ma J, Xiao X (2012) Enhancing muscle membrane repair by gene delivery of MG53 ameliorates muscular dystrophy and heart failure in delta-Sarcoglycan-deficient hamsters. Mol Ther 20(4):727–735PubMedPubMedCentralGoogle Scholar
  57. 57.
    Cai C, Masumiya H, Weisleder N, Matsuda N, Nishi M, Hwang M, Ko JK, Lin P, Thornton A, Zhao X, Pan Z, Komazaki S, Brotto M, Takeshima H, Ma J (2009) MG53 nucleates assembly of cell membrane repair machinery. Nat Cell Biol 11(1):56–64PubMedGoogle Scholar
  58. 58.
    Gushchina LV, Bhattacharya S, McElhanon KE, Choi JH, Manring H, Beck EX, Alloush J, Weisleder N (2017) Treatment with recombinant human MG53 protein increases membrane integrity in a mouse model of limb girdle muscular dystrophy 2B. Mol Ther 25(10):2360–2371PubMedPubMedCentralGoogle Scholar
  59. 59.
    Swierczek M, Izsvak Z, Ivics Z (2012) The sleeping beauty transposon system for clinical applications. Expert Opin Biol Ther 12(2):139–153PubMedGoogle Scholar
  60. 60.
    Escobar H, Schowel V, Spuler S, Marg A, Izsvak Z (2016) Full-length dysferlin transfer by the hyperactive Sleeping Beauty transposase restores dysferlin-deficient muscle. Mol Ther Nucleic Acids 5:e277PubMedPubMedCentralGoogle Scholar
  61. 61.
    Turan S, Farruggio AP, Srifa W, Day JW, Calos MP (2016) Precise correction of disease mutations in induced pluripotent stem cells derived from patients with limb girdle muscular dystrophy. Mol Ther 24(4):685–696PubMedPubMedCentralGoogle Scholar
  62. 62.
    Woudt L, Di Capua GA, Krahn M, Castiglioni C, Hughes R, Campero M, Trangulao A, Gonzalez-Hormazabal P, Godoy-Herrera R, Levy N, Urtizberea JA, Jara L, Bevilacqua JA (2016) Toward an objective measure of functional disability in dysferlinopathy. Muscle Nerve 53(1):49–57PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Généthon INSERM, U951, INTEGRARE Research Unit, University Paris–SaclayEvryFrance

Personalised recommendations